BioSpace News Archive

Revive Therapeutics Ltd. is pleased to announce that the U.S. Food & Drug Administration has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Continuous glucose monitoring tracks glucose levels of people with type I or type II diabetes through a device that monitors levels throughout the day.

The following is attributed to FDA Commissioner Stephen M. Hahn, M.D., and Susan Mayne, Ph.D., director of the Center for Food Safety and Applied Nutrition.

Helix, the leading population genomics company, today announced that it has been awarded $33.4 M in funding from the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx) program.

Not for distribution by US newswire or in United States NESS-ZIONA, Israel, July 31, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“ Vaxil ” or the “ Company ”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has cancelled its previously announced brokered private placement, offering up to 35,294,118 units (the “Units”) at a price of $0.085 per Unit (see press release date May 26, 2020). The Company has determined

MorphoSys AG announces that the U.S. Food and Drug Administration has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.

First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need

First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need

The following quote is attributed to Frank Yiannas, Deputy Commissioner for Food Policy and Response:

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces that the Company’ s registered share capital and number of outstanding shares and votes have increased during the month of July.